Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"IGC Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IGC Commences Phase 1 of Cannabinoid Clinical Trial for Alzheimer\u2019s Patients","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"November 2020","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I"},{"orgOrder":0,"company":"IGC Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Update On IGC\u2019s Phase 1 Clinical Trial on Alzheimer\u2019s Patients","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2021","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I"},{"orgOrder":0,"company":"IGC Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"India Globalization Capital (IGC) Completes Cohort 1 of its Phase 1 THC-Based Clinical Trial on Alzheimer\u2019s Patients","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"May 2021","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I"},{"orgOrder":0,"company":"IGC Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IGC Completes Cohort 2 of its Phase 1 THC-Based Clinical Trial on Alzheimer\u2019s Patients","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"June 2021","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I"},{"orgOrder":0,"company":"IGC Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IGC Completes the Final Cohort of Its Phase 1 Clinical Trial on Alzheimer\u2019s Patients","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"June 2021","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I"},{"orgOrder":0,"company":"IGC Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phase 1 Clinical Trial Provides Valuable Insights on Safe and Effective Dosing of IGC-AD1 for Alzheimer\u2019s Patients","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"December 2021","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I"},{"orgOrder":0,"company":"IGC Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clinical Trial on Alzheimer\u2019s Patients Indicates Positive Safety and Tolerability Data for IGC\u2019s THC-Based Investigational New Drug","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"December 2021","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I"},{"orgOrder":0,"company":"IGC Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IGC Announces Issuance of Second Patent for the Treatment of Alzheimer\u2019s Using THC","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"September 2022","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II"},{"orgOrder":0,"company":"IGC Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IGC Pharma Receives Notice of Allowance for Patent on Seizures","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical"},{"orgOrder":0,"company":"IGC Pharma","sponsor":"Bradbury Asset Management","pharmaFlowCategory":"D","amount":"$3.0 million","upfrontCash":"Undisclosed","newsHeadline":"IGC Pharma Announces a $3 Million Private Placement of its Common Stock","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"July 2023","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II"},{"orgOrder":0,"company":"IGC Pharma","sponsor":"O-Bank Co., Ltd.","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"IGC Pharma Secures $12 Million Line of Credit from O-Bank Strengthening Efforts in Alzheimer's Research","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"July 2023","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II"},{"orgOrder":0,"company":"IGC Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IGC Pharma Expands Phase 2 Trial of IGC-AD1 to Include the University of Puerto Rico","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"August 2023","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II"},{"orgOrder":0,"company":"IGC Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IGC Pharma Activates ClinCloud, One of 12 Sites in Ongoing Phase 2b Alzheimer\u2019s Trial","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2024","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II"},{"orgOrder":0,"company":"IGC Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IGC Pharma Breakthrough: Preclinical Trial Data Shows TGR-63 Reduces Plaque in Alzheimer\u2019s","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical"},{"orgOrder":0,"company":"IGC Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IGC Pharma Announces Positive Interim Results for IGC-AD1 in Reducing Alzheimer\u2019s Agitation","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II"},{"orgOrder":0,"company":"IGC Pharma","sponsor":"Bradbury Asset Management","pharmaFlowCategory":"D","amount":"$3.0 million","upfrontCash":"Undisclosed","newsHeadline":"IGC Pharma Announces $3 Million Unregistered Private Placement of its Common Stock","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2024","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II"},{"orgOrder":0,"company":"IGC Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Promising Results: TGR-63 Enhances Memory in Alzheimer's Mouse Model","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical"},{"orgOrder":0,"company":"IGC Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IGC-AD1\u2019s Interim Phase 2 Data Show a Reduction in Alzheimer\u2019s Agitation at Week Two","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II"}]

    Find Clinical Drug Pipeline Developments & Deals by IGC Pharma

    Menu

    IGC Pharma

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              IGC Pharma

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              IGC-AD1’s Interim Phase 2 Data Show a Reduction in Alzheimer’s Agitation at Week Two

              Details:

              IGC-AD1 (tetrahydrocannabinol) is a small molecule drug that targets neuroinflammation and CB1 receptor dysfunction. It is being evaluated for the treatment of alzheimer disease.

              Lead Product(s): Tetrahydrocannabinol

              Therapeutic Area: Neurology Product Name: IGC-AD1

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable April 16, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              IGC Pharma

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              IGC Pharma Announces $3 Million Unregistered Private Placement of its Common Stock

              Details:

              The net proceeds will be used for the advancement of company's investigational medicines including IGC-AD1, a natural THC-based oral formulation, as a treatment for agitation in dementia from Alzheimer’s disease.

              Lead Product(s): Tetrahydrocannabinol,Melatonin

              Therapeutic Area: Neurology Product Name: IGC-AD1

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Bradbury Asset Management

              Deal Size: $3.0 million Upfront Cash: Undisclosed

              Deal Type: Private Placement March 26, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              IGC Pharma

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              IGC Pharma Announces Positive Interim Results for IGC-AD1 in Reducing Alzheimer’s Agitation

              Details:

              IGC-AD1 is the first natural cannabis-based formulation, which is being evaluated for the treatment of agitation in dementia from alzheimer’s disease.

              Lead Product(s): IGC-AD1

              Therapeutic Area: Neurology Product Name: IGC-AD1

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable March 20, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              IGC Pharma

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Promising Results: TGR-63 Enhances Memory in Alzheimer's Mouse Model

              Details:

              TGR-63 is a therapeutic candidate designed to disrupt the structure of the amyloid-β (Aβ) peptide, mitigating symptoms such as memory loss and disrupted learning ability, signs of cognitive impairment. It is being evaluated for the treatment of Alzheimer's disease.

              Lead Product(s): TGR-63

              Therapeutic Area: Neurology Product Name: TGR-63

              Highest Development Status: Preclinical Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable February 28, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              IGC Pharma

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              IGC Pharma Breakthrough: Preclinical Trial Data Shows TGR-63 Reduces Plaque in Alzheimer’s

              Details:

              TGR-63 is a patent pending molecule designed to disrupt the structure of Aβ plaque aggregation by disrupting intermolecular interactions and destabilizing their assembly. It is being evaluated in preclinical studies for the treatment of Alzheimer's disease.

              Lead Product(s): TGR-63

              Therapeutic Area: Neurology Product Name: TGR-63

              Highest Development Status: Preclinical Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable January 23, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              IGC Pharma

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              IGC Pharma Activates ClinCloud, One of 12 Sites in Ongoing Phase 2b Alzheimer’s Trial

              Details:

              IGC-AD1, a combination medicine with a CB1 receptor partial agonist with anti-neuroinflammatory properties. It is under phase 2 clinical development for the treatment of dementia due to Alzheimer’s.

              Lead Product(s): Tetrahydrocannabinol,Melatonin

              Therapeutic Area: Neurology Product Name: IGC-AD1

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable January 17, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              IGC Pharma

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              IGC Pharma Expands Phase 2 Trial of IGC-AD1 to Include the University of Puerto Rico

              Details:

              IGC-AD1, a low-dose tetrahydrocannabinol based formulation, currently in Phase 2 of clinical trials as a potential treatment for agitation in dementia due to alzheimer’s.

              Lead Product(s): Tetrahydrocannabinol

              Therapeutic Area: Neurology Product Name: IGC-AD1

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable August 02, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              IGC Pharma

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              IGC Pharma Secures $12 Million Line of Credit from O-Bank Strengthening Efforts in Alzheimer's Research

              Details:

              The funding will support IGC’s working capital needs primarily related to its Alzheimer’s research, with IGC-AD1, a low-dose tetrahydrocannabinol based formulation, currently in Phase 2 of clinical trials as a potential treatment for agitation in dementia due to Alzheimer’s.

              Lead Product(s): Tetrahydrocannabinol,Melatonin

              Therapeutic Area: Neurology Product Name: IGC-AD1

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: O-Bank Co., Ltd.

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Financing July 07, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              IGC Pharma

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              IGC Pharma Announces a $3 Million Private Placement of its Common Stock

              Details:

              The funds will support the advancement of the Company’s Phase-2 clinical trial of IGC-AD1 (tetrahydrocannabinol), the Company’s promising investigational drug candidate designed to address agitation in dementia caused by Alzheimer's disease.

              Lead Product(s): Tetrahydrocannabinol,Melatonin

              Therapeutic Area: Neurology Product Name: IGC-AD1

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Bradbury Asset Management

              Deal Size: $3.0 million Upfront Cash: Undisclosed

              Deal Type: Private Placement July 06, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              IGC Pharma

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              IGC Pharma Receives Notice of Allowance for Patent on Seizures

              Details:

              IGC-501 (cannabinoid-based therapy) patent filing on the use of cannabinoids in the treatment of seizures. The formulation also received an intent to grant from the European Patent Office.

              Lead Product(s): Cannabinoid-based Therapy

              Therapeutic Area: Neurology Product Name: IGC-501

              Highest Development Status: Preclinical Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable June 06, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY